Rocaglamide

Rocaglamide is an inhibitor of HSP90 and NF-kB used in studies of NF-kB Signaling and Immune Signaling. It is especially relevant in cancer, immunology, and inflammation models, where defined compound exposure can be linked to inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses.

By inhibiting HSP90 and NF-kB, Rocaglamide can be used to examine inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses. This context is compatible with NF-kB reporter, cytokine, and inflammation assays and immune activation, cytokine-response, and mediator-profiling assays, as well as transcriptional, biochemical, or phenotypic comparisons linked to the annotated pathway state. In cancer, immunology, and inflammation models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving HSP90 and NF-kB
• Pathway perturbation studies connected to NF-kB Signaling and Immune Signaling
• Concentration-response inhibition and target-dependence studies
• Phenotypic profiling in cancer, immunology, and inflammation models

Overall, Rocaglamide is appropriate when a defined chemical perturbant is needed to connect HSP90 and NF-kB with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, immunology, and inflammation models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.